Key Insights

Highlights

Success Rate

92% trial completion (above average)

Published Results

88 trials with published results (47%)

Research Maturity

147 completed trials (79% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

7.0%

13 terminated out of 187 trials

Success Rate

91.9%

+5.4% vs benchmark

Late-Stage Pipeline

7%

13 trials in Phase 3/4

Results Transparency

60%

88 of 147 completed with results

Key Signals

88 with results92% success13 terminated

Data Visualizations

Phase Distribution

174Total
Not Applicable (38)
Early P 1 (5)
P 1 (33)
P 2 (85)
P 3 (7)
P 4 (6)

Trial Status

Completed147
Unknown13
Terminated13
Withdrawn7
Recruiting5
Not Yet Recruiting1

Trial Success Rate

91.9%

Benchmark: 86.5%

Based on 147 completed trials

Clinical Trials (187)

Showing 20 of 20 trials
NCT07318480Not ApplicableRecruiting

Transcranial Direct Current Stimulation (tDCS) for Treatment of Cocaine Use Disorder

NCT02455479Phase 1RecruitingPrimary

Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals

NCT03266939Phase 1WithdrawnPrimary

Rebalancing the Serotonergic System in Cocaine Dependence

NCT05974202Not ApplicableNot Yet Recruiting

rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder

NCT04907357Not ApplicableCompleted

rTMS for Stimulant Use Disorders

NCT02111798Phase 2Completed

Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence

NCT02927236Not ApplicableTerminated

Theta-Burst Stimulation as a Treatment for Reducing Cocaine Use

NCT06125054Phase 2Recruiting

Ketamine and Neurofeedback-Training: Effects on Neuroplasticity in Cocaine Addiction

NCT04994821Phase 2Completed

TDCS to Reduce Craving in Cocaine Addiction- Phase 2 Study

NCT03833583Not ApplicableCompleted

TDCS for Cocaine Addiction Craving

NCT03527485Not ApplicableCompleted

Imaging Synaptic Density in Cocaine and Opiate Addiction In Vivo Using 11UCB-J PET

NCT05562349Phase 2Active Not RecruitingPrimary

Clavulanic Acid for the Treatment of Cocaine Use Disorder

NCT03471182Phase 1CompletedPrimary

Investigation of Cocaine Addiction Using mGluR5 PET and fMRI

NCT06189690Not ApplicableRecruitingPrimary

Effect of HF rTMS on Serum BDNF in Cocaine Use Disorder

NCT00439049Recruiting

Substance Abuse Pre-Treatment Screening Study

NCT06159387Phase 4UnknownPrimary

Randomized, Double-blind, Placebo-controlled Cannabis Extract x Placebo for Cocaine Addicts

NCT02563769Phase 1CompletedPrimary

Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study

NCT02124941Phase 1CompletedPrimary

Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 1H-MRS

NCT04411914Phase 1CompletedPrimary

Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid

NCT02255357Phase 2CompletedPrimary

Investigation of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients.

Scroll to load more

Research Network

Activity Timeline